跳至主要内容
附件 II 条目 175 已修订 20 十月 2010

Methylphenidate (INN) and its salts

Methylphenidate (INN) and its salts 在附件 II 中被列为在欧盟市场上市的化妆品的禁用物质。

禁用物质— 附件 II, 欧盟法规 1223/2009
条目: 175

记录详情

化学名称

Methylphenidate (INN) and its salts

监管信息

法规

(EC) 2009/1223

查看该法案设定的所有条目

关键数据

附件
条目编号
175

化学身份与性质

CAS 113-45-1 的 PubChem 二维化学结构
CAS 113-45-1PubChem CID 4158

Methylphenidate

Methyl phenyl(piperidin-2-yl)acetate is a amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group. It is a methyl ester, a member of piperidines and a beta-amino acid ester. — ChEBI

IUPAC 名称
methyl 2-phenyl-2-piperidin-2-ylacetate
分子式
C14H19NO2
分子量
233.31 g/mol
精确质量
233.141578849 Da
XLogP3
0.2
拓扑极性表面积
38.3 Ų
氢键供体
1
氢键受体
3
共价单元
1
已定义的立体中心
0

又称

MethylphenidanPhenidylateCalocainPlimasineMethyl phenidylacetateMetilfenidatoMethylphenidatumMethyl phenidate
另有 16 个已报告名称
4311/B CibaDaytranaalpha-Phenyl-2-piperidineacetic acid methyl esterMethyl alpha-phenyl-alpha-(2-piperidyl)acetateNCI-C56280Methyl 2-phenyl-2-(piperidin-2-yl)acetate2-Piperidineacetic acid, alpha-phenyl-, methyl esterCotempla XR-ODTMethyl alpha-phenyl-alpha-2-piperidinylacetatealpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl esterMetilfenidat hydrochlorideThreo-dl-methylphenidatePrc-063Methylphenidate extended releaseRitalineRefChem:6033
外部数据库标识符

来自其他科学数据库的证据

NIH PubChem PUG-View
标识符精确匹配4158

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Oral. Readily absorbed in a biphasic manner when orally administered (tablets) to children diagnosed with ADHD and to healthy adults. In children and adults males, after administration of a single oral dose of Ritalin LA and Ritalin given in two doses 4 hours apart, peak plasma concentration is reached approximately 2 hours for the first phase and 5-6 hours for the second phase. The absolute oral bioavailability of methylphenidate in children was 22±8% for d-methylphenidate and 5±3% for l-methylphenidate. These low values suggest that methylphenidate is highly metabolized presystemically. 来源: Toxin and Toxin Target Database (T3DB)
  • Signal: Warning 来源: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H341 (100%): Suspected of causing genetic defects [Warning Germ cell mutagenicity] 来源: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. 来源: European Chemicals Agency (ECHA)
  • Signal: Danger 来源: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] 来源: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P233, P260, P264, P270, P271, P284, P301+P317, P304+P340, P330, P342+P316, P403, and P501 (click each P-code to see the statement) 来源: Hazardous Substances Data Bank (HSDB)
  • Health Effects: Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion. 来源: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: IDENTIFICATION AND USE: Methylphenidate Hydrochloride is a psychostimulant used to treat different behavioral disorders. Indications: Used to treat narcolepsy and hyperkinetic states in children (as an adjunct to psychological, educational and social measures) for amphetamine, dextroamphetamine and ethylphenidate. It is misused for performance enhancement and relief of fatigue. Abuse either orally or by injection is extremely common. HUMAN EXPOSURE AND TOXICITY: Main risks include: Acute central nervous system (CNS) stimulation, cardiotoxicity causing tachycardia, arrhythmias, hypertension and cardiovascular collapse. High risk of dependency and abuse. Cardiovascular effects include: palpitation, chest pain, tachycardia, arrhythmias and hypertension; cardiovascular collapse can occur in severe poisoning. Myocardial ischemia, infarction and ventricular dysfunction are described. CNS effects include: stimulation of CNS, tremor, restlessness, agitation, insomnia, increased motor activity, headache, convulsions, coma and hyperreflexia. Stroke and cerebral vasculitis have been observed. Gastrointestinal effects include: vomiting, diarrhea and cramps. Genitourinary effects include: incre 来源: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: The first step in a medication overdose is to immediately contact a poison control center for the appropriate management steps. Doses that exceed 60 mg of the immediate-release formulation or 120 mg of the extended-release formulation can be considered toxic. If the overdosed quantity is unknown, the patient should be assessed for signs and symptoms such as tremors, hyperreflexia, convulsions, euphoria, confusion, hallucinations, delirium, flushing, and fever, in addition to the common adverse effects mentioned above. Supportive care with supplemental oxygen, intravenous fluids, and external cooling methods is the mainstay of treatment. Multiple studies have shown that benzodiazepines are an option, especially if dystonia, agitation, or convulsions are present. 来源: StatPearls
  • Toxicity Summary: Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result. 来源: Toxin and Toxin Target Database (T3DB)
  • Environmental Bioconcentration: An estimated BCF of 3 was calculated in fish for methylphenidate(SRC), using a log Kow of 0.20(1) and a regression-derived equation(2). According to a classification scheme(2), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC). 来源: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to have low mobility in soil(SRC). The pKa of methylphenidate is 8.9(3), indicating that this compound will exist partially in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the neutral species of methylphenidate from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), using a fragment constant estimation method(5). Methylphenidate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2015). 来源: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to adsorb to suspended solids and sediment(SRC). Volatilization of the neutral species from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). A pKa of 8.9(5) indicates methylphenidate will exist partially in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(6), an estimated BCF of 3(SRC), from its log Kow of 0.20(7) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Base-catalyzed second-order hydrolysis rate constant half-lives of 23 and 2.3 years at pH values of 7 and 8, respectively(2), suggest that hydrolysis may be a slow environmental fate process. Biodegradation data in water were not available(SRC, 2015). 来源: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), methylphenidate, which has an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase methylphenidate is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 1 hr(SRC), calculated from its rate constant of 1.1X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase methylphenidate may be removed from the air by wet and dry deposition(SRC). Methylphenidate contains chromophores that absorb at wavelengths >290 nm(4) and, therefore, may be susceptible to direct photolysis by sunlight(SRC). 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Methylphenidate (DEA Code Number: 1724) is a Schedule II controlled substance. 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Schedule II Controlled Substance: (A) The drug or other substance has a high potential for abuse; (B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions; and (C) Abuse of the drug or other substances may lead to severe psychological or physical dependence. 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION (VET) 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Central Nervous System Stimulants; Dopamine Uptake Inhibitors 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg) in Switzerland (2009): >250; Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 9090; Consumption (g per capita) in Switzerland (2009): 0.032; Consumption (g per capita; approx.) in Germany (2009): 0.012; Consumption (g per capita) in the USA (2002): 0.032; Excretion rate: 0.1; Calculated removal (%): 92.1 来源: NORMAN Suspect List Exchange
  • Uses: For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. 来源: Toxin and Toxin Target Database (T3DB)

映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录

科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。

其他来源的覆盖范围和匹配状态
来源结果已检查
NIH PubChem PUG-View精确匹配2026-08-31

已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。

于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

该记录的直接匹配结果有限,因此同时显示附件 II 中的相邻条目。

附件 II 180
同一附件中的相邻记录

Fenozolone (INN)

CAS: 15302-16-6
EC: 239-339-6

附件 II 对 Methylphenidate (INN) and its salts 意味着什么

Methylphenidate (INN) and its salts 被列为欧盟化妆品法规 1223/2009 附件 II 中的禁用物质,不得有意添加。第 17 条另行规定了在良好生产规范下技术上不可避免、且符合第 3 条安全要求的非有意微量存在的情形。

配方师必须筛查其成分和原料,确保均不含该物质。供应商应在被要求时提供证明不含该物质的文件。

本页还显示 12 条相关附件记录,其标识符、附件逻辑或命名模式存在重叠。

合规核查清单

  • 核实该物质不存在于所有原料和成品配方中。
  • 向原料供应商索取不含该物质的确认函或 CoA。
  • 将筛查结果记录在产品信息档案 (PIF) 中。

常见问题

是。Methylphenidate (INN) and its salts 列于欧盟化妆品法规 1223/2009 的附件 II,禁止作为化妆品成分有意添加。第 17 条对在良好生产规范下技术上不可避免的非有意微量存在规定了狭窄的例外,前提是产品仍符合第 3 条的安全要求。

CAS 113-45-1 是化学文摘社 (Chemical Abstracts Service) 分配给 Methylphenidate (INN) and its salts 的唯一数字标识符。在化妆品合规工作中,CAS 编号用于在监管数据库、原料规格书和安全评估报告之间交叉引用该物质。如果同一物质在不同条件下或不同附件中出现,多个欧盟附件条目可能共用同一 CAS 编号。

使用本站的 INCI 检查器工具粘贴您的完整成分表 (INCI),并对照所有附件 II–VI 条目进行扫描。该工具会突出显示与限用、禁用或致敏原标记记录相匹配的成分。这有助于对成品配方或原料声明进行快速合规筛查。

附件 II 记录 Methylphenidate (INN) and its salts 的来源说明

本页概述欧盟委员会公开化妆品资料中 Methylphenidate (INN) and its salts 的一条附件 II 记录,并在可用时补充关联的清单或标识符匹配。

请使用本记录页面查看 Methylphenidate (INN) and its salts 的附件 II 条件,但任何最终监管决定都应对照现行官方附件措辞和来源文件确认。

工具与后续步骤

检查您的配方

粘贴完整的 INCI 成分表,一次性检出 Methylphenidate (INN) and its salts 及其他被标记的欧盟附件记录。

INCI 检查器

条目对比

将 Methylphenidate (INN) and its salts 与另一条附件记录并排对比,查看限制、浓度和附件归属的差异。

对比

浏览附件

查看附件 II 中的所有记录,并对比该附件中各物质的监管条件。

打开附件 II